MedTrace Logo

a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors

NCT06166836 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2026-03-25

No results posted yet for this study

Summary

This is a phase 1b/II, open-label study to evaluate the safety, tolerability, pharmacokinetics and antitumor activities of D-1553 in combination with IN10018 in subjects with locally advanced or metastatic solid tumor with KRAS G12C mutation.

Conditions

Interventions

DRUG

D1553

D1553 orally taken，600mg twice a day

DRUG

IN10018（Ifebemtinib）

IN10018 orally taken once daily at approximately the same time each day

Sponsors & Collaborators

  • InventisBio Co., Ltd

    collaborator INDUSTRY

  • InxMed (Shanghai) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Zhengbo Song · Study Principal Investigator

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-12
Primary Completion
2027-12-31
Completion
2028-12-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06166836 on ClinicalTrials.gov